|
Jun 17
|
BioRestorative Announces Share Repurchase Program
|
|
Jun 13
|
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
|
|
Jun 10
|
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
|
|
Jun 9
|
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
|
|
Feb 10
|
BRTX-100 Front and Center at ORS 2025
|
|
Oct 10
|
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
|
|
Oct 3
|
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
|
Jul 23
|
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
|
|
Jun 27
|
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
|
|
Jun 13
|
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
|
|
Jun 11
|
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
|
|
Dec 3
|
11 Most Volatile Stocks Under $5 For Day Trading
|
|
May 4
|
BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
|